Yurpeak vs Mounjaro: What Is Actually the Difference?
Short answer: they are the same medicine. Both are Eli Lilly's tirzepatide at identical prices. The only real difference is who distributes it, and that difference decides which one your pharmacy actually has in stock.
ALTRcare Medical Team
Clinical Editorial
Yurpeak and Mounjaro are the same drug. Both contain tirzepatide, both are manufactured by Eli Lilly, both come in the same six weekly doses from 2.5 mg to 15 mg, and Lilly has confirmed they are priced identically. The difference is commercial, not clinical: Mounjaro is sold through Lilly's own network, concentrated in metro cities, while Yurpeak is distributed and promoted by Cipla, whose pharmacy reach extends far deeper into tier-2 and tier-3 India.
| Mounjaro | Yurpeak | |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide (identical) |
| Manufacturer | Eli Lilly | Eli Lilly (same factories) |
| Distributor | Eli Lilly India | Cipla |
| India launch | March 2025 | December 2025 |
| Formats | Vials and KwikPen | KwikPen only |
| Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg weekly | Same six strengths |
| Monthly price | ₹13,125 to ₹25,781 | Identical by agreement |
| Where you'll find it | Metro pharmacies | Wider reach, including smaller cities |
Why two brands of one drug exist
In October 2025, Eli Lilly and Cipla signed a distribution and promotion agreement creating a second Indian brand of tirzepatide. Lilly keeps manufacturing the medicine; Cipla puts its distribution muscle behind it. The stated goal was access: Mounjaro's sales were strong but concentrated where Lilly had a field presence, and demand from smaller cities was going unmet. Yurpeak launched in December 2025 to fill that gap.
This is not the same thing as a generic. A generic is a different company's version of the molecule, made in its own plants after a patent expires. Tirzepatide's patents in India run well into the 2030s, so no generic exists. Yurpeak is Lilly's own product wearing a second label, closer to how one movie releases in two cinema chains.
The one practical difference: format
Mounjaro launched in India in vials, with KwikPen devices following. Yurpeak is available only as the KwikPen, the pre-filled injector pen, across all six strengths. If your prescription specifies a vial-and-syringe format for cost or preference reasons, that means Mounjaro. If you are on the pen, either brand fills the prescription identically.
What to tell the pharmacist
A prescription for tirzepatide can be filled with whichever brand is in stock. If Mounjaro is unavailable, asking for Yurpeak at the same dose gets you the exact same medicine at the same price, and vice versa.
Efficacy, side effects and switching
Because the medicine is identical, there is no efficacy comparison to make. The SURMOUNT and SURPASS trial results that apply to Mounjaro apply equally to Yurpeak: tirzepatide is a dual GIP and GLP-1 receptor agonist, and at higher doses it produces greater average weight loss than semaglutide in head-to-head trials. Side-effect profiles, titration schedules and precautions are also identical. Switching between the brands mid-treatment is not a medical switch at all; you continue the same dose on the same weekly day.
Considering tirzepatide?
ALTRcare's Yurpeak program starts at ₹13,999 a month including the medication, doctor consultations, titration and follow-up. Take the free 2-minute assessment and a doctor will confirm whether tirzepatide suits you.
Which should you ask for?
Whichever your pharmacy reliably stocks. In metros, both circulate; outside metros, Yurpeak is increasingly the one on the shelf. The decision that actually matters is upstream: whether tirzepatide is the right molecule for you at all versus semaglutide, which now costs a fraction as much in India. That is a conversation about your BMI, your metabolic profile, your budget over 6 to 12 months, and how much weight loss is clinically appropriate, and it belongs with a doctor rather than a brand comparison.
Key takeaways
- Yurpeak and Mounjaro are both Eli Lilly tirzepatide: same molecule, same doses, same price.
- Yurpeak is distributed by Cipla and reaches more cities; that is the entire difference.
- Yurpeak comes only as a KwikPen; Mounjaro also exists in vials.
- Neither is a generic. Tirzepatide has no generics in India until well into the 2030s.
- A tirzepatide prescription can be filled with either brand interchangeably.
Frequently asked questions
Is Yurpeak the same as Mounjaro?
Yes. Both are tirzepatide manufactured by Eli Lilly, in the same six weekly doses, at the same price. Yurpeak is distributed by Cipla under a 2025 agreement; Mounjaro is distributed by Lilly directly.
Is Yurpeak cheaper than Mounjaro?
No. Under the Lilly-Cipla agreement, Yurpeak is priced the same as Mounjaro: ₹13,125 per month at the 2.5 mg starting dose up to about ₹25,781 per month at the highest doses.
Is Yurpeak a generic version of Mounjaro?
No. It is the identical Lilly-manufactured product under a second brand name. Generic tirzepatide cannot legally launch in India until Lilly's patents expire in the 2030s.
Can I switch from Mounjaro to Yurpeak?
Yes, seamlessly. Because the medicine is identical, you continue the same dose on your usual injection day. Confirm the swap with your prescribing doctor so your records stay accurate.
Does Yurpeak work as well as Mounjaro for weight loss?
Identically, because it is the same medicine. All tirzepatide clinical trial data applies equally to both brands.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
